Literature DB >> 10801130

CpG methylation is maintained in human cancer cells lacking DNMT1.

I Rhee1, K W Jair, R W Yen, C Lengauer, J G Herman, K W Kinzler, B Vogelstein, S B Baylin, K E Schuebel.   

Abstract

Hypermethylation is associated with the silencing of tumour susceptibility genes in several forms of cancer; however, the mechanisms responsible for this aberrant methylation are poorly understood. The prototypic DNA methyltransferase, DNMT1, has been widely assumed to be responsible for most of the methylation of the human genome, including the abnormal methylation found in cancers. To test this hypothesis, we disrupted the DNMT1 gene through homologous recombination in human colorectal carcinoma cells. Here we show that cells lacking DNMT1 exhibited markedly decreased cellular DNA methyltransferase activity, but there was only a 20% decrease in overall genomic methylation. Although juxtacentromeric satellites became significantly demethylated, most of the loci that we analysed, including the tumour suppressor gene p16INK4a, remained fully methylated and silenced. These results indicate that DNMT1 has an unsuspected degree of regional specificity in human cells and that methylating activities other than DNMT1 can maintain the methylation of most of the genome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10801130     DOI: 10.1038/35010000

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  122 in total

Review 1.  Above and within the genome: epigenetics past and present.

Authors:  F D Urnov; A P Wolffe
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-04       Impact factor: 2.673

Review 2.  The marks, mechanisms and memory of epigenetic states in mammals.

Authors:  V K Rakyan; J Preis; H D Morgan; E Whitelaw
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

3.  The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases.

Authors:  Chi-Neu Tsai; Chia-Lung Tsai; Ka-Po Tse; Hwan-You Chang; Yu-Sun Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-10       Impact factor: 11.205

Review 4.  DNA methylation changes in gastrointestinal disease.

Authors:  Minoru Toyota; Fumio Itoh; Takefumi Kikuchi; Ayumi Satoh; Toshiro Obata; Hiromu Suzuki; Suguru Ishii; Takao Endo; Takashi Tokino; Kohzoh Imai
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

5.  Dnmt3L is a transcriptional repressor that recruits histone deacetylase.

Authors:  Rachel Deplus; Carmen Brenner; Wendy A Burgers; Pascale Putmans; Tony Kouzarides; Yvan de Launoit; François Fuks
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

6.  Insights into the role of DNA methylation in disease through the use of mouse models.

Authors:  Melissa Conerly; William M Grady
Journal:  Dis Model Mech       Date:  2010 May-Jun       Impact factor: 5.758

7.  Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.

Authors:  Ang Li; Noriyuki Omura; Seung-Mo Hong; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2010-02-01       Impact factor: 4.742

8.  Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy.

Authors:  Yeonjoo Jung; Jinah Park; Tai Young Kim; Jung-Hyun Park; Hyun-Soon Jong; Seock-Ah Im; Keith D Robertson; Yung-Jue Bang; Tae-You Kim
Journal:  J Mol Med (Berl)       Date:  2007-06-15       Impact factor: 4.599

Review 9.  Nutrition in early life, and risk of cancer and metabolic disease: alternative endings in an epigenetic tale?

Authors:  Graham C Burdge; Karen A Lillycrop; Alan A Jackson
Journal:  Br J Nutr       Date:  2008-12-12       Impact factor: 3.718

10.  RFTS-deleted DNMT1 enhances tumorigenicity with focal hypermethylation and global hypomethylation.

Authors:  Bo-Kuan Wu; Szu-Chieh Mei; Charles Brenner
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.